S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:APTX

Aptinyx (APTX) Stock Forecast, Price & News

$0.07
0.00 (0.00%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.07
$0.08
50-Day Range
$0.06
$0.18
52-Week Range
$0.05
$0.74
Volume
689,064 shs
Average Volume
3.82 million shs
Market Capitalization
$4.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.38

Aptinyx MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
1,827.1% Upside
$1.38 Price Target
Short Interest
Healthy
2.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Aptinyx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars


APTX stock logo

About Aptinyx (NASDAQ:APTX) Stock

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Stock News Headlines

Aptinyx (APTX) to Release Quarterly Earnings on Wednesday
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Aptinyx (APTX) Set to Announce Earnings on Wednesday
Aptinyx Inc. (NASDAQ:APTX) Short Interest Update
Brokerages Set Aptinyx Inc. (NASDAQ:APTX) PT at $1.50
WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Aptinyx Inc. (NASDAQ:APTX) Short Interest Up 48.6% in March
Aptinyx (NASDAQ: APTX)
H.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)
Aptinyx Inc. (NASDAQ: APTX)
Aptinyx Inc. (APTX)
See More Headlines
Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Company Calendar

Last Earnings
3/30/2023
Today
5/28/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.38
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+1,827.1%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-64,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$0.27 per share

Miscellaneous

Free Float
61,026,000
Market Cap
$4.83 million
Optionable
Not Optionable
Beta
1.33

Key Executives

  • Andrew Kidd
    CEO, Chief Financial & Accounting Officer
  • Craig R. Jalbert
    President, Secretary, Treasurer & Director
  • Kathryn King
    Senior Vice President-Clinical & CMC Operations
  • Patrick Flavin
    Head-Media & Investor Relations
  • Tim Noffke
    Chief of Staff & Vice President-Program Management













APTX Stock - Frequently Asked Questions

Should I buy or sell Aptinyx stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" APTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APTX, but not buy additional shares or sell existing shares.
View APTX analyst ratings
or view top-rated stocks.

What is Aptinyx's stock price forecast for 2023?

8 equities research analysts have issued 1-year price targets for Aptinyx's shares. Their APTX share price forecasts range from $0.50 to $2.00. On average, they expect the company's stock price to reach $1.38 in the next year. This suggests a possible upside of 1,827.1% from the stock's current price.
View analysts price targets for APTX
or view top-rated stocks among Wall Street analysts.

How have APTX shares performed in 2023?

Aptinyx's stock was trading at $0.2853 on January 1st, 2023. Since then, APTX stock has decreased by 75.0% and is now trading at $0.0714.
View the best growth stocks for 2023 here
.

Are investors shorting Aptinyx?

Aptinyx saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,300,000 shares, a drop of 41.7% from the April 30th total of 2,230,000 shares. Based on an average trading volume of 4,450,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.9% of the shares of the company are sold short.
View Aptinyx's Short Interest
.

When is Aptinyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our APTX earnings forecast
.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) issued its earnings results on Thursday, March, 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

What other stocks do shareholders of Aptinyx own?
When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.67%), Acadian Asset Management LLC (0.56%), Virtu Financial LLC (0.41%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel and Robert J Hombach.
View institutional ownership trends
.

How do I buy shares of Aptinyx?

Shares of APTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $0.07.

How much money does Aptinyx make?

Aptinyx (NASDAQ:APTX) has a market capitalization of $4.83 million and generates $1 million in revenue each year. The company earns $-64,850,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for the company is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at investors@aptinyx.com.

This page (NASDAQ:APTX) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -